Oct 29, 2020
Lallemand Pharma launched in production the PMBL tablets with an improved natural mint taste..
The taste of a medication is one of the key attributes determining patient acceptability and compliance, as well as, market acceptance. That’s why, a careful attention is paid to the aroma characteristics of the products developed by Lallemand Pharma. Although it is a key for all oral dosage forms, and particularly important for sublingual formulations that are savoured more intensely than conventional oral tablets and capsules directly swallowed.
Children differ from adults in many aspects of pharmacotherapy, especially taste preferences. It is essential that medicines are formulated to best suit a child’s age, size, physiologic condition, and treatment requirements. 
Lallemand Pharma wished to implement an improved flavour to encourage patient compliance, more particularly in paediatric population. The unpleasant taste occasionally found in some oral pharmaceutical formulations can hinder acceptability, especially in children and elderly patient, resulting in lower efficiency of the medicines.
The aroma analyses were carried out in partnership with Amatsi laboratories: two improved mint flavours were proposed to our company. The mandate was to stick to the same technical specifications than the former aroma, while improving the savour. The tests were trialed by a sensory analysis panel to select the new mint aroma.
Figure : Sensory analysis panel for the mint aroma proposal
Lallemand Pharma is proud to announce the production and commercialization of the PMBL sublingual tablets with the new improved taste early October 2020. The production has been realized first for Italy, then Argentina, and Ukraine will follow in December.
Understanding the importance of the sensorial experience when taking oral medicine, Lallemand Pharma has always been keen to offer the best quality pharmaceuticals for a better patient experience.
 Ivanovska V, Rademaker CM, van Dijk L, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014 Aug;134(2):361-72. doi: 10.1542/peds.2013-3225. Epub 2014 Jul 14. PMID: 25022739.